Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
Launched by OPHTHOTECH CORPORATION · Aug 8, 2014
Trial Information
Current as of June 20, 2025
Terminated
Keywords
ClinConnect Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy in either a "Simultaneous" Regimen (Fovista® administered with anti-VEGF same day) or "Pre-Treatment" Regimen (monotherapy Fovista® Day 0 followed by Fovista® administered in combination with anti-VEGF Day 2).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects of either gender aged ≥ 50 years
- • All fluorescein angiographic subtypes with presence of active choroidal neovascularization
- Exclusion Criteria:
- • Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication
- • Subjects with subfoveal scar or subfoveal atrophy
- • Any ocular or periocular infection in the past twelve (12) weeks
- • History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant
About Ophthotech Corporation
Ophthotech Corporation is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. With a focus on addressing unmet medical needs in conditions such as age-related macular degeneration and other vision-threatening disorders, Ophthotech is committed to advancing its proprietary drug candidates through rigorous clinical trials. The company's expertise in ophthalmology and its robust pipeline reflect a strong commitment to improving patient outcomes and enhancing the quality of life for individuals affected by debilitating eye diseases. Through strategic partnerships and a dedication to scientific excellence, Ophthotech aims to lead the way in transforming the landscape of retinal treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Augusta, Georgia, United States
Cincinnati, Ohio, United States
Sacramento, California, United States
Santa Ana, California, United States
Beverly Hills, California, United States
Phoenix, Arizona, United States
Abilene, Texas, United States
Ladson, South Carolina, United States
Jackson, Michigan, United States
Oak Forest, Illinois, United States
Minneapolis, Minnesota, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials